Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children

Determination of Hearing Status in Children Receiving Intra-Arterial Carboplatin for Intraocular Retinoblastoma

The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.

Inclusion Criteria:

• Signed informed consent indicating awareness of the investigational nature of the protocol.

• Children with RB aged 3 months and older who are scheduled to receive their first dose of IA carboplatin chemotherapy.

  • Retinoblastoma is rarely seen in children over 8 years old, however we will not include an upper age range so as not to exclude any possible participants

Exclusion Criteria:

• Children with known and documented preexisting hearing loss.